Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
3.
Cutis ; 111(2): 82-83, 2023 Feb.
Article in English | MEDLINE | ID: mdl-37075178

ABSTRACT

Achieving hemostasis in cutaneous surgery on bony or irregular surfaces can be challenging; typical pressure dressings that act by mechanical occlusion with petrolatum gauze can be inadequate. We offer the use of bone wax as a practical hemostatic agent that can be (1) molded to provide ideal occlusion and pressure without adhering to wound surfaces and (2) painlessly and simply removed.


Subject(s)
Hemostatics , Humans , Hemostatics/therapeutic use , Waxes , Hemostasis , Palmitates
4.
JAMA Dermatol ; 159(4): 450-451, 2023 04 01.
Article in English | MEDLINE | ID: mdl-36811868

ABSTRACT

A woman in her 80s initially presented with numerous, primarily photodistributed, crusted, and ulcerated plaques of the trunk and extremities and a medical history of essential thrombocytosis treated with hydroxyurea for 14 years. What is your diagnosis?


Subject(s)
Extremities , Hydroxyurea , Humans , Hydroxyurea/adverse effects
5.
J Am Acad Dermatol ; 86(6): 1246-1257, 2022 06.
Article in English | MEDLINE | ID: mdl-34890701

ABSTRACT

BACKGROUND: The role of adjuvant radiotherapy for high-risk cutaneous squamous cell carcinomas after surgery with negative margins is unclear. OBJECTIVE: To conduct a systematic review and meta-analysis examining the risk of poor outcomes for patients treated with surgery alone versus surgery and adjuvant radiotherapy. METHODS: A comprehensive search of articles was executed in PubMed, Embase, and the Cochrane Database. Random-effected meta-analyses were conducted. RESULTS: Thirty-three studies comprising 3867 high-risk cutaneous squamous cell carcinomas were included. There were no statistically significant differences in poor outcomes between the surgery only group and surgery with adjuvant radiotherapy group. Estimates for local recurrence for the surgery alone group versus the surgery with adjuvant radiotherapy group were 15.2% (95% confidence interval [CI], 6.3%-27%) versus 8.8% (95% CI, 1.6%-20.9%); for regional metastases, 11.5% (95% CI, 7.2%-16.7%) versus 4.4% (95% CI, 0%-18%); for distant metastases, 2.6% (95% CI, 0.6%-6%) versus 1.7% (95% CI, 0.2%-4.5%); and for disease-specific deaths, 8.2% (95% CI, 1.2%-20.6%) versus 19.7% (95% CI, 3.8%-43.7%), respectively. LIMITATIONS: Retrospective nature of most studies with the lack of sufficient patient-specific data. CONCLUSIONS: For patients with high-risk cutaneous squamous cell carcinomas treated with margin-negative resection, there were no significant differences in poor outcomes between the surgery only group and the surgery with adjuvant radiotherapy group. Randomized controlled trials are necessary to define the benefit of adjuvant radiotherapy in this setting.


Subject(s)
Carcinoma, Squamous Cell , Skin Neoplasms , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/radiotherapy , Carcinoma, Squamous Cell/surgery , Humans , Margins of Excision , Radiotherapy, Adjuvant , Retrospective Studies , Skin Neoplasms/pathology , Skin Neoplasms/radiotherapy , Skin Neoplasms/surgery
7.
J Vasc Surg Venous Lymphat Disord ; 9(4): 1031-1040, 2021 07.
Article in English | MEDLINE | ID: mdl-34144767

ABSTRACT

BACKGROUND: Superficial venous disease of the lower extremity has a significant impact on quality of life. Both truncal and tributary vein reflux contribute to this disease process. Endovenous foam sclerotherapy is a widely used technique throughout the world for the management of superficial venous reflux and ultrasound guidance improves its safety and efficacy. METHODS: A PubMed search for ultrasound-guided foam sclerotherapy (UGFS) was conducted and all abstracts were reviewed to identify clinical trials and systematic reviews for a full-text analysis. Additional articles were also identified through searching the references of the selected studies. RESULTS: The production of foam for sclerotherapy in a 1:3 or 1:4 ratio of air to sclerosant is optimal in a low silicone, low-volume syringe system. Physiologic gas may decrease any side effects, with the trade-off of decreased foam stability. Proper technique with appropriate sterility and cleansing protocols are paramount for safe and effective treatment. The technical success of UGFS for great saphenous vein disease is inferior to endothermal and surgical modalities and retreatment is more common. However, the clinical improvement in patient-reported quality of life is similar between these three modalities. When used for tributary veins in combination with endothermal approaches of the truncal veins, UGFS has high rates of success with excellent patient satisfaction. UGFS has demonstrated an excellent safety profile comparable with or superior to other modalities. CONCLUSIONS: With proper technique, UGFS is safe and effective for the management of superficial venous disease.


Subject(s)
Lower Extremity/blood supply , Sclerotherapy/methods , Venous Insufficiency/therapy , Humans , Lower Extremity/diagnostic imaging , Nervous System Diseases/etiology , Quality of Life , Sclerosing Solutions/administration & dosage , Sclerotherapy/adverse effects , Stockings, Compression , Ultrasonography , Varicose Veins/therapy , Venous Insufficiency/diagnostic imaging , Venous Thrombosis/etiology
10.
Cutis ; 106(2): E8-E11, 2020 Aug.
Article in English | MEDLINE | ID: mdl-32941565

ABSTRACT

This case series discusses 3 patients with long-standing eczematous or psoriasiform dermatitis, demonstrated by multiple biopsies. Following off-label treatment with dupilumab, all 3 patients had clinical expansion of disease, with histopathologic features consistent with cutaneous T-cell lymphoma (CTCL) on subsequent biopsy. We postulate that this expansion likely was secondary to an exacerbation of extant CTCL following exposure to dupilumab. A proposed mechanism of promotion of CTCL is based on the functional increase in IL-13 available for binding at the upregulated IL-13 receptor (IL-13R) α2 site on cells, following blockade of the α1 receptor with dupilumab. This progression merits further investigation.


Subject(s)
Antibodies, Monoclonal, Humanized/administration & dosage , Dermatitis/drug therapy , Eczema/drug therapy , Lymphoma, T-Cell, Cutaneous/diagnosis , Antibodies, Monoclonal, Humanized/adverse effects , Biopsy , Dermatitis/pathology , Disease Progression , Eczema/pathology , Female , Humans , Interleukin-13/immunology , Lymphoma, T-Cell, Cutaneous/etiology , Lymphoma, T-Cell, Cutaneous/pathology , Male , Middle Aged , Off-Label Use , Psoriasis/drug therapy , Psoriasis/pathology
12.
Skinmed ; 15(4): 311-313, 2017.
Article in English | MEDLINE | ID: mdl-28859749

ABSTRACT

A 64-year-old white woman was originally diagnosed with histiocytic lymphoma in 1977. She had bilateral lymph node biopsies of the groin, chemotherapy, and radiation therapy after her diagnosis had been confirmed pathologically. She was treated with prednisone and vincristine.


Subject(s)
Lymphangiectasis/etiology , Lymphangioma/surgery , Vulvar Neoplasms/surgery , Vulvectomy/adverse effects , Female , Humans , Middle Aged , Remission, Spontaneous , Vulvectomy/methods
13.
Dermatol Online J ; 23(2)2017 Feb 15.
Article in English | MEDLINE | ID: mdl-28329499

ABSTRACT

This report details an acral melanoma in-situ on theright plantar foot that was successfully treated withMohs micrographic surgery and secondary intentionwound healing.


Subject(s)
Foot , Melanoma/surgery , Skin Neoplasms/surgery , Wound Healing , Aged , Female , Humans , Melanoma/pathology , Mohs Surgery , Neoplasm Staging , Skin Neoplasms/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...